{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:02:49Z","timestamp":1786132969011,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Significance Statement<\/jats:title>\n                    <jats:p>Studies examining the cost-effectiveness of hepatitis C virus (HCV) screening methods or frequencies are lacking. The authors examined the cost-effectiveness of the Kidney Disease Improving Global Outcomes (KDIGO) 2018 guidelines' recommendation to test in-center hemodialysis patients for HCV every 6 months. They demonstrated that with current HCV prevalence, incidence, and treatment practices in patients receiving hemodialysis, screening for HCV every 6 months is not cost-effective under a willingness-to-pay threshold of US$150,000, even if baseline survival rates doubled or all patients received treatment on diagnosis. Screening only at dialysis initiation or every 2 years are cost-effective approaches, however, with incremental cost-effectiveness ratios of $82,739 and $140,193, respectively, per quality-adjusted life-year saved compared with no screening. These data suggest that reevaluation of HCV screening guidelines in hemodialysis patients should be considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>National guidelines recommend twice-yearly hepatitis C virus (HCV) screening for patients receiving in-center hemodialysis. However, studies examining the cost-effectiveness of HCV screening methods or frequencies are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We populated an HCV screening, treatment, and disease microsimulation model with a cohort representative of the US in-center hemodialysis population. Clinical outcomes, costs, and cost-effectiveness of the Kidney Disease Improving Global Outcomes (KDIGO) 2018 guidelines\u2013endorsed HCV screening frequency (every 6 months) were compared with less frequent periodic screening (yearly, every 2 years), screening only at hemodialysis initiation, and no screening. We estimated expected quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) between each screening strategy and the next less expensive alternative strategy, from a health care sector perspective, in 2019 US dollars. For each strategy, we modeled an HCV outbreak occurring in 1% of centers. In sensitivity analyses, we varied mortality, linkage to HCV cure, screening method (ribonucleic acid versus antibody testing), test sensitivity, HCV infection rates, and outbreak frequencies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Screening only at hemodialysis initiation yielded HCV cure rates of 79%, with an ICER of $82,739 per QALY saved compared with no testing. Compared with screening at hemodialysis entry only, screening every 2 years increased cure rates to 88% and decreased liver-related deaths by 52%, with an ICER of $140,193. Screening every 6 months had an ICER of $934,757; in sensitivity analyses using a willingness-to-pay threshold of $150,000 per QALY gained, screening every 6 months was never cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The KDIGO-recommended HCV screening interval (every 6 months) does not seem to be a cost-effective use of health care resources, suggesting that re-evaluation of less-frequent screening strategies should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.2022030245","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T15:35:10Z","timestamp":1670945710000},"page":"205-219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers"],"prefix":"10.1681","volume":"34","author":[{"given":"Rachel L.","family":"Epstein","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Department of Pediatrics, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannishtha","family":"Pramanick","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Baptiste","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Buzzee","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Reese","sequence":"additional","affiliation":[{"name":"Department of Medicine, Renal-Electrolyte Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Sawinski","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, Weill Cornell College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"B1-20240826","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2018.11.009","article-title":"Mortality and kidney transplantation outcomes among hepatitis C virus-seropositive maintenance dialysis patients: a retrospective cohort study","volume":"73","author":"Sawinski","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B2-20240826","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B3-20240826","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement","volume":"323","author":"Owens","year":"2020","journal-title":"JAMA."},{"key":"B4-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for hepatitis C screening among adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep."},{"key":"B5-20240826","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","article-title":"Executive summary of the 2018 KDIGO hepatitis C in CKD Guideline: welcoming advances in evaluation and management","volume":"94","author":"Jadoul","year":"2018","journal-title":"Kidney Int."},{"key":"B7-20240826","first-page":"1","article-title":"Recommendations for preventing transmission of infections among chronic hemodialysis patients","volume":"50","author":"Alter","year":"2001","journal-title":"MMWR Recomm Rep."},{"key":"B9-20240826","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1525-139X.2005.18108.x","article-title":"National surveillance of dialysis-associated diseases in the United States, 2002","volume":"18","author":"Finelli","year":"2005","journal-title":"Semin Dial."},{"key":"B10-20240826","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10620-007-9966-2","article-title":"A cost-identification analysis of screening and surveillance of hepatitis C infection in a prospective cohort of dialysis patients","volume":"53","author":"Somsouk","year":"2008","journal-title":"Dig Dis Sci."},{"key":"B13-20240826","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12879-017-2773-2","article-title":"Diagnostic accuracy of tests to detect hepatitis C antibody: a meta-analysis and review of the literature","volume":"17","author":"Tang","year":"2017","journal-title":"BMC Infect Dis."},{"key":"B14-20240826","doi-asserted-by":"crossref","first-page":"ofw266","DOI":"10.1093\/ofid\/ofw266","article-title":"Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis C virus genotype 1","volume":"4","author":"Linas","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"B15-20240826","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med."},{"key":"B17-20240826","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11606-020-05701-9","article-title":"HCV testing and treatment in a national sample of US federally qualified health centers during the opioid epidemic","volume":"35","author":"Assoumou","year":"2020","journal-title":"J Gen Intern Med."},{"key":"B18-20240826","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.amjmed.2020.05.029","article-title":"Hepatitis C management at federally qualified health centers during the opioid epidemic: a cost-effectiveness study","volume":"133","author":"Assoumou","year":"2020","journal-title":"Am J Med."},{"key":"B19-20240826","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1093\/cid\/ciab779","article-title":"Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study","volume":"75","author":"Barocas","year":"2022","journal-title":"Clin Infect Dis."},{"key":"B20-20240826","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12882-016-0271-1","article-title":"Mortality and illicit drug dependence among hemodialysis patients in the United States: a retrospective cohort analysis","volume":"17","author":"Grubbs","year":"2016","journal-title":"BMC Nephrol."},{"key":"B21-20240826","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/infdis\/jiv220","article-title":"Hepatitis C virus reinfection and spontaneous clearance of reinfection\u2014the InC3 study","volume":"212","author":"Sacks-Davis","year":"2015","journal-title":"J Infect Dis."},{"key":"B22-20240826","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-5-13","article-title":"The role of hemodialysis machines dedication in reducing hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study","volume":"5","author":"Shamshirsaz","year":"2004","journal-title":"BMC Nephrol."},{"key":"B23-20240826","first-page":"CD006420","article-title":"Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units","volume":"8","author":"Bravo Zu\u00f1iga","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"B24-20240826","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"B25-20240826","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA."},{"key":"B26-20240826","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/ajt.15791","article-title":"Dialysis facility referral and start of evaluation for kidney transplantation among patients treated with dialysis in the Southeastern United States","volume":"20","author":"Patzer","year":"2020","journal-title":"Am J Transplant."},{"key":"B27-20240826","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology."},{"key":"B28-20240826","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","article-title":"Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle","volume":"195","author":"Tsui","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"B29-20240826","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep4.1627","article-title":"A population-based intervention to improve care cascades of patients with hepatitis C virus infection","volume":"5","author":"Scott","year":"2020","journal-title":"Hepatol Commun."},{"key":"B30-20240826","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0033354919888228","article-title":"Improved hepatitis C cure cascade outcomes among urban baby boomers in the direct-acting antiviral era","volume":"135","author":"Dupont","year":"2019","journal-title":"Public Health Rep."},{"key":"B31-20240826","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/hep.29362","article-title":"Impact of an electronic health record alert in primary care on increasing hepatitis C screening and curative treatment for baby boomers","volume":"66","author":"Konerman","year":"2017","journal-title":"Hepatology."},{"key":"B32-20240826","doi-asserted-by":"crossref","first-page":"ofaa322","DOI":"10.1093\/ofid\/ofaa322","article-title":"Persistent challenges in the hepatitis C virus care continuum for patients in a central Texas public health System","volume":"7","author":"Reader","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"B33-20240826","doi-asserted-by":"crossref","first-page":"e0218388","DOI":"10.1371\/journal.pone.0218388","article-title":"HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center","volume":"14","author":"Calner","year":"2019","journal-title":"PLoS One."},{"key":"B34-20240826","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0272989X08315240","article-title":"Health-state utilities in liver disease: a systematic review","volume":"28","author":"McLernon","year":"2008","journal-title":"Med Decis Making."},{"key":"B35-20240826","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1360-0443.2008.02153.x","article-title":"Preference-weighted health-related quality of life measures and substance use disorder severity","volume":"103","author":"Pyne","year":"2008","journal-title":"Addiction."},{"key":"B36-20240826","doi-asserted-by":"crossref","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLoS Med."},{"key":"B38-20240826","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med."},{"key":"B39-20240826","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/JCM.03236-15","article-title":"Performance of the new aptima HCV quant Dx assay in comparison to the Cobas TaqMan HCV2 test for use with the high pure system in detection and quantification of hepatitis C virus RNA in plasma or serum","volume":"54","author":"Schalasta","year":"2016","journal-title":"J Clin Microbiol."},{"key":"B41-20240826","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.15585\/mmwr.mm6450a5","article-title":"Notes from the field: hepatitis C outbreak in a dialysis clinic\u2014Tennessee, 2014","volume":"64","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B43-20240826","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/sdi.12761","article-title":"Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention","volume":"32","author":"Nguyen","year":"2019","journal-title":"Semin Dial."},{"key":"B45-20240826","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cid\/cix798","article-title":"Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings","volume":"66","author":"Assoumou","year":"2018","journal-title":"Clin Infect Dis."},{"key":"B46-20240826","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/aje\/kwg209","article-title":"Longitudinal patterns of drug injection behavior in the ALIVE Study Cohort, 1988\u20132000: description and determinants","volume":"158","author":"Galai","year":"2003","journal-title":"Am J Epidemiol."},{"key":"B47-20240826","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int J Drug Policy."},{"key":"B48-20240826","doi-asserted-by":"crossref","first-page":"e027491","DOI":"10.1136\/bmjopen-2018-027491","article-title":"Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update","volume":"9","author":"Erman","year":"2019","journal-title":"BMJ Open."},{"key":"B50-20240826","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2019","journal-title":"Liver Int."},{"key":"B51-20240826","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology."},{"key":"B52-20240826","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int."},{"key":"B53-20240826","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med."},{"key":"B55-20240826","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"Davis","year":"2011","journal-title":"J Clin Gastroenterol."},{"key":"B56-20240826","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal","volume":"158","author":"Coffin","year":"2013","journal-title":"Ann Intern Med."},{"key":"B57-20240826","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making."},{"key":"B59-20240826","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jmv.1890390104","article-title":"Prevalence of hepatitis C virus infection among long-term hemodialysis patients: detection of hepatitis C virus RNA in plasma","volume":"39","author":"Sakamoto","year":"1993","journal-title":"J Med Virol."},{"key":"B60-20240826","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ki.1997.139","article-title":"Hepatitis C virus infection in dialysis and renal transplantation","volume":"51","author":"Pereira","year":"1997","journal-title":"Kidney Int."},{"key":"B61-20240826","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0391398817752326","article-title":"HCV viraemia in anti-HCV-negative haemodialysis patients: do we need HCV RNA detection test?","volume":"41","author":"Papadopoulos","year":"2018","journal-title":"Int J Artif Organs."},{"key":"B62-20240826","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12985-015-0238-z","article-title":"Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients","volume":"12","author":"Vidales-Braz","year":"2015","journal-title":"Virol J."},{"key":"B63-20240826","doi-asserted-by":"crossref","first-page":"52","DOI":"10.18683\/germs.2021.1240","article-title":"The prevalence of HCV RNA positivity in anti-HCV antibodies-negative hemodialysis patients in Thrace Region. Multicentral study","volume":"11","author":"Konstantinidou","year":"2021","journal-title":"Germs."},{"key":"B64-20240826","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/cid\/ciz383","article-title":"Cost-effectiveness and budgetary impact of hepatitis C virus testing, treatment, and linkage to care in US prisons","volume":"70","author":"Assoumou","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B65-20240826","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/AOG.0000000000003062","article-title":"Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care","volume":"133","author":"Tasillo","year":"2019","journal-title":"Obstet Gynecol."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2022030245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:26:45Z","timestamp":1786130805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2022030245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2022030245","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2022-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}